company background image
APLT logo

Applied Therapeutics NasdaqGM:APLT Stock Report

Last Price

US$6.85

Market Cap

US$725.3m

7D

-0.7%

1Y

721.5%

Updated

27 Mar, 2024

Data

Company Financials +

Applied Therapeutics, Inc.

NasdaqGM:APLT Stock Report

Market Cap: US$725.3m

APLT Stock Overview

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.

APLT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Applied Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Applied Therapeutics
Historical stock prices
Current Share PriceUS$6.85
52 Week HighUS$9.39
52 Week LowUS$0.76
Beta1.83
1 Month Change29.25%
3 Month Change120.97%
1 Year Change721.54%
3 Year Change-63.48%
5 Year Changen/a
Change since IPO-27.13%

Recent News & Updates

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Recent updates

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Feb 16
Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Nov 13
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Aug 11
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

May 19
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11
Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26
Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18
How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24
Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Applied Therapeutics EPS misses by $0.21

Nov 12

Shareholder Returns

APLTUS BiotechsUS Market
7D-0.7%0.9%0.4%
1Y721.5%10.3%28.8%

Return vs Industry: APLT exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: APLT exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is APLT's price volatile compared to industry and market?
APLT volatility
APLT Average Weekly Movement24.9%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: APLT's share price has been volatile over the past 3 months.

Volatility Over Time: APLT's weekly volatility has increased from 18% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201625Shoshana Shendelmanhttps://www.appliedtherapeutics.com

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.

Applied Therapeutics, Inc. Fundamentals Summary

How do Applied Therapeutics's earnings and revenue compare to its market cap?
APLT fundamental statistics
Market capUS$725.32m
Earnings (TTM)-US$119.76m
Revenue (TTM)US$9.99m

72.6x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APLT income statement (TTM)
RevenueUS$9.99m
Cost of RevenueUS$53.91m
Gross Profit-US$43.91m
Other ExpensesUS$75.85m
Earnings-US$119.76m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.13
Gross Margin-439.43%
Net Profit Margin-1,198.47%
Debt/Equity Ratio-1.8%

How did APLT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.